Dapsone-induced Methemoglobinemia Case Report

Area of Science:

• Hematology
• Toxicology
• Biochemistry

Background:

• Methemoglobinemia is a rare blood disorder characterized by elevated methemoglobin levels, impairing oxygen transport to tissues and causing hypoxemia.
• It can be acquired, often due to oxidizing drugs, or inherited.
• Standard treatment involves methylene blue, but alternatives are needed when it fails or is contraindicated.

Observation:

• This case study focuses on methemoglobinemia treatment when standard methylene blue therapy proves insufficient.
• The patient received two doses of methylene blue without complete resolution of methemoglobinemia.
• Ascorbic acid was administered as a subsequent treatment option.

Findings:

• Oral ascorbic acid demonstrated efficacy in treating methemoglobinemia after two doses of methylene blue.
• Ascorbic acid acts as an antioxidant, protecting tissues from free radical damage.
• It aids in reducing methemoglobin by supporting the nicotinamide adenine dinucleotide phosphate-dependent glutathione system.

Implications:

• Ascorbic acid presents a viable alternative therapeutic option for methemoglobinemia, particularly in cases resistant to or intolerant of methylene blue.
• This finding is especially relevant for managing methemoglobinemia caused by drugs with long half-lives, where rebound or non-resolution can occur.
• Further research into ascorbic acid's role in methemoglobinemia management could expand treatment strategies for this rare disorder.